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Abstract  
Objectives 
To compare, head-to-head, fractional flow reserve (FFR) derived from coronary CTA (FFRCT) and 
cardiac magnetic resonance (CMR) stress perfusion imaging for prediction of standard of care 
guided coronary revascularization in patients with stable chest pain and obstructive coronary artery 
disease (CAD) by coronary CTA.  
Background 
FFRCT is a novel modality for non-invasive functional testing. The clinical utility of FFRCT 
compared to CMR stress perfusion imaging in symptomatic patients with CAD is unknown.  
Methods 
Prospective study of patients, n=110, with stable angina pectoris and >1 coronary stenosis >50% by 
coronary CTA. All patients underwent coronary angiography (ICA). Revascularization was FFR-
guided in stenoses ranging from 30-90%. FFRCT <0.80 in >1 coronary artery or a reversible 
perfusion defect (>2 segments) by CMR categorized patients with ischemia. FFRCT and CMR 
analysed by core laboratories blinded for patient management. 
Results 
A total of 38 patients (35%) underwent revascularization. Per-patient diagnostic performance for 
identifying standard of care guided revascularization, (95% confidence interval) yielded a sensitivity 
of 97% (86-100) for FFRCT versus 47% (31- 64) for CMR, p<0.001; corresponding specificity was 
42% (30-54) versus 88% (78-94), p<0.001; negative predictive value of 97% (91-100) versus 76% 
(67-85), p<0.05; positive predictive value of 47% (36-58) versus 67% (49-84), p<0.05; and accuracy 
of 61% (51-70) versus 74% (64-82), p>0.05, respectively. 
Conclusions 
In patients with stable chest pain referred to ICA based on coronary CTA, FFRCT and CMR yielded 
similar overall diagnostic accuracy. Sensitivity for prediction of revascularization was highest for 
FFRCT, while specificity was highest for CMR. 
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Abbreviations 
CAD = Coronary Artery Disease 
CMR = Cardiac Magnetic Resonance 
CTA = Computed Tomography Angiography 
CX = Circumflex Coronary Artery 
FFR = Fractional Flow Reserve 
FFRCT = Coronary CTA derived Fractional Flow Reserve 
LAD = Left Anterior Descending Coronary Artery 
LM = Left Main Coronary Artery 
MPI = Myocardial Perfusion Imaging 
RCA = Right Coronary Artery.  
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Introduction 
Current guidelines recommend myocardial perfusion imaging (MPI) as the frontline testing strategy 
in symptomatic patients with intermediate risk of coronary artery disease (CAD) (1,2) before 
referral to invasive coronary angiography and decision making on coronary revascularization. Meta-
analyses (3,4) have indicated that stress perfusion imaging by cardiac magnetic resonance (CMR) is 
more accurate than commonly applied perfusion techniques by single photon emission computed 
tomography (SPECT) for the diagnosis of CAD. Still, CMR has not yet been generally implemented 
as a first-line testing strategy in patients with symptoms of stable CAD. Coronary computed 
tomography angiography (CTA) has evolved as an alternative due to a high diagnostic performance 
for exclusion of CAD (5). However, the hemodynamic significance of lesions cannot be assessed by 
coronary CTA. Computational fluid dynamics and individual image-based modelling now allows 
estimation of coronary blood flow and - pressure from standard acquired coronary CTA datasets (6). 
Subsequent processing of the data derived from computed tomography permits calculation of non-
invasive fractional flow reserve (FFRCT). The new metric, FFRCT, has good diagnostic performance 
using invasive FFR as the reference standard (7, 8) and its utility in clinical practice has been 
demonstrated by improvements in diagnostic sensitivity compared to SPECT (9), diagnostic yield of 
coronary angiography (10) and prognosis (11).  
A direct comparison of the clinical utility of FFRCT and CMR as second-line sequential 
testing strategies has not previously been assessed. Consequently, the aim of this study was to 
compare, head-to-head, FFRCT and CMR for predicting standard of care guided coronary 
revascularization in patients with new onset stable chest pain and obstructive CAD as determined by 
coronary CTA.  
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Methods 
Study design and patient cohort 
This study is a prespecified sub-study of the Dan-NICAD trial (12), which was designed to compare 
the diagnostic performance of SPECT and CMR in diagnosing invasively determined obstructive 
CAD in consecutive symptomatic patients having obstructive CAD as determined by coronary CTA. 
This sub-study represents a head-to-head comparison of the clinical utility of FFRCT and CMR-
testing for the prediction of standard of care guided coronary revascularization.   
Coronary CTA is used as the recommended first-line testing strategy in patients with 
new onset stable chest pain in Denmark. In general, patients with a low-intermediate pre-test risk of 
having obstructive CAD and no prior revascularization, a body mass index <40 kg/m2, a glomerular 
filtration rate >45 ml/min and no persistent atrial fibrillation are eligible for coronary CTA. 
Consequently, the Dan-NICAD criteria for inclusion were new onset stable chest pain in low-
intermediate risk patients referred for a first-line coronary CTA to rule-out CAD. This sub-study 
included patients randomized to the CMR-arm of the Dan-NICAD trial due to the presence of at 
least one coronary stenosis >50% as determined by coronary CTA. Exclusion criteria were known 
CAD, inability to undergo adenosine testing or CMR, allergy to iodinated contrast media, non-
cardiac illness with life expectancy less than 2 years or pregnancy. All patients underwent 
subsequent coronary angiography. The decision on revascularization was guided by invasive FFR in 
stenosis ranging from 30-90% and was made at the discretion of the operator or the Heart Team. 
The study flow chart is illustrated in Figure 1. 
FFRCT and CMR assessments were performed at core-laboratories and test results were 
unknown to interventionalists and surgeons of the Heart Team. To mimic clinical practice, the CMR 
core-laboratory had information regarding symptoms, medicine, risk factors and the result of the 
coronary CTA; while the FFRCT core-laboratory only had access to the coronary CTA-dataset.  
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Informed consent was obtained from all participants. The study was approved by The 
Central Denmark Region Committees on Health Research Ethics (S-20150085) and registered by 
the Data Protection Registry (2008-58-0035; 1563) of The Central Region of Denmark.  
 
Coronary CTA  
Coronary CTA was performed at two centres in Denmark. Both centres used a 320-slice volume CT 
scanner (Aquillion One, Toshiba Medical Systems, Japan) with prospective electrocardiographic 
(ECG) gating. Oral beta-blockers or ivabradine were administered if necessary, targeting a heart rate 
<60 beats/min. Administration of sublingual nitroglycerine was given to all patients without known 
side effects of this drug. An initial non-enhanced scan for calcium scoring was performed. Coronary 
CTA was assessed and graded visually by skilled CT cardiologists. Lesions were reported using an 
18-segment model (13) and classified as proximal if located in segments 1, 2, 5, 6, 7, 11 or 13; all 
other lesion locations were classified as distal. 
 
Invasive procedures and revascularization 
Ingestion of caffeine was not allowed for 24 hours prior to invasive procedures. Coronary 
angiography was performed by standard techniques. FFR measurements (St. Jude Medical, MN, 
USA and Volcano, San Diego, CA, USA) were performed in coronary stenosis ranging from 30 to 
90% (visual assessment by the treating physician) and a reference diameter >2mm. Maximal 
hyperaemia was induced by intravenous adenosine (140 mcg/kg/min). Recordings of aortic and 
distal coronary pressures were obtained during sustained hyperaemia (after 2 minutes of adenosine 
infusion). Patients were classified as having obstructive CAD, if >1 high-grade stenosis >90% 
(visual assessment) by invasive coronary angiography or if >1 coronary artery had an FFR-value 
<0.80 distal to stenosis ranging from 30-90%. Physicians responsible for downstream patient 
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management were blinded to the results of FFRCT and CMR analyses, including those performing 
the ICA and FFR investigations. All patients revascularized by coronary artery by-pass surgery 
(CABG) or percutaneous coronary intervention (PCI) or a combination of the two were registered.  
 
FFRCT  
Standard acquired coronary CTA data sets were transmitted for core-laboratory analysis (HeartFlow 
Inc., Redwood City, California, USA). The principles behind FFRCT computation have been 
described in detail previously (6). Any FFRCT value in the major coronary arteries >1.8 mm in 
diameter, including side branches, were registered. Patients were classified as having obstructive 
CAD, if the per-patient lowest FFRCT-value was <0.80 (distal-tip FFRCT-value). In addition, patients 
were classified according to the per-patient lowest FFRCT-value registered 2 cm distal to lesion 
(lesion-specific FFRCT-value) using an identical threshold-value for ischemia (14). Occluded vessels 
were assigned an FFRCT-value of 0.50. The distal-tip FFRCT-value was used for the main 
comparisons with CMR.  
 
CMR  
Patients were instructed to stop ingestion of caffeine for 24 hours prior to stress studies. CMR scans 
were conducted using a 1.5 Tesla system (Siemens MAGNETOM Avanto, Siemens Healthcare 
GmbH, Erlangen, Germany) as previously described (15). In brief, stress perfusion imaging was 
conducted either after intravenous injection of 0.4 mg (5 ml) of Regadenoson (Lexiscan, Astellas 
Pharma, USA) or infusion of adenosine 140 mcg/kg/min over 4 min. Gadovist (Bayer Schering 
Pharma AG, Germany) or Dotarem (GD-DOTA, Guerbet LCC, USA), were used as contrast agents. 
CMR data were analyzed by a core laboratory (William Harvey Research Institute, Queen Mary 
University of London, London, UK). CMR-image quality was graded as high, medium or poor. 
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Stress-perfusion CMR images were evaluated according to a standard 16-segment model by visual 
analysis (16). Perfusion defects were defined as subendocardial or transmural signal changes by 
stress imaging or irreversible defects by late gadolinium enhancement (LGE) imaging. Abnormality 
of CMR studies were graded based on the number of segments involved: 0-1=normal; 2-4=small; 5-
7=moderate; >8=large. Patients were classified as having obstructive CAD if reversible changes 
from rest to stress were registered in >2 contiguous segments. 
 
Statistical analyses  
This sub-study of the Dan-NICAD trial was planned and designed before the start of any data 
analysis in the main study (12). McNemar’s test was used to compare the sensitivity, specificity and 
accuracy of FFRCT and CMR as well was comparison of minimum distal-tip- and minimal lesion-
specific FFRCT-values in relation to classification of patient-level ischemia. Logistic regression 
using cluster robust standard errors was used to compare PPV and NPV. Fisher’s exact test was used 
for comparison of proportions between subgroups. Associations between proportions of 
revascularized patients/proportions of patients with significant CAD and patient level minimum 
FFRCT -values and size of CMR-perfusion defects, respectively, were tested using weighted linear 
regression with robust standard errors. A p-value <0.05 was considered statistically significant. All 
statistical analyses were performed using Stata software, version 15.1 (Stata Corp, College Station, 
Texas).  
 
Role of the funding source and the core-laboratory at HeartFlow  
The funders had no role in study design, data collection, analysis, interpretation, or writing of the 
report. HeartFlow only had access to the coronary CTA datasets and did not perform any data-
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handling or data analysis, did not influence interpretation of data and did not participate in writing of 
the manuscript. The contract with HeartFlow on FFRCT-analysis was made using the price at cost.  
 
Results 
Between September 2014 and March 2016, 1675 consecutive symptomatic patients were enrolled in 
the Dan-NICAD trial. A stenosis >50% was diagnosed by coronary CTA in 386 patients, of whom 
197 patients were randomized to undergo CMR and invasive coronary angiography/FFR. Of these, 
58 patients did not have a complete dataset, and 29 (21%) of coronary CTA datasets were rejected 
for FFRCT-analysis, Figure 1. Basic characteristics of the 110 patients, who constituted the study 
cohort are shown in Table 1. Median (IQR) time delay between coronary CTA and coronary 
catheterization was 32 (25-39) days. 
 
Coronary CTA 
Relevant preparation variables and Agatston scores are presented in Table 2.  
 
Invasive procedures and revascularization 
Overall 44 patients were diagnosed with obstructive CAD. Because of small vessel dimension, 
vessel tortuosity or paucity of symptoms at the time of angiography, 6 of these patients were not 
revascularized; 3 patients with obstructive stenosis (FFR < 0.80 [range 0.76-0.80]) and 3 patients 
with an occluded coronary artery. The number of revascularized patients, n (%), was not 
significantly different in this sub-study, 38 (35), compared to the number of revascularizations 
performed in patients in the CMR-arm of the Dan-NICAD cohort, 25 (36), who were excluded due 
to missing data.  
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A total of 55 vessels were revascularized and distributed as follows, n (%): LM, 1 (2); 
LAD, 27 (49); CX, 9 (16); RCA 11 (20); side branches 7 (13). Revascularized lesions were located 
in proximal coronary segments in 34 (89%) patients. In 26 patients with a maximal stenosis >90%, 
23 (88%) patients were revascularized, while 12 of these 26 patients had an FFR performed in 
another stenosis ranging from 30-90%. In 57 patients with a maximal stenosis ranging from 30-90%, 
15 (26%) patients underwent revascularization. No patient with stenosis <30% was revascularized. 
Three out of 25 PCI-procedures were performed in chronic total occlusions; three out of 13 surgical 
procedures as off-pump coronary artery by-pass operations. An overview of invasive procedures and 
given treatments is presented in Table 3.   
 
FFRCT 
The number, n (%), of patients classified with obstructive CAD, FFRCT-value <0.80, was higher 
when classification was based on the per-patient minimum distal-tip - compared to per-patient 
minimum lesion-specific FFRCT-value, 79 (72) versus 55 (50), respectively, p<0.001. The overall 
distributions of patient-level FFRCT-values and the associations to the occurrence of significant 
CAD and revascularization are shown in Tables 4a and 4b. Of 55 revascularized vessels, 50 (91%) 
vessels had an FFRCT-value <0.80. All occluded vessels were correctly identified by FFRCT. 
 
CMR 
Stress studies were performed using regadenoson (n=48) or adenosine (n=62). Image quality was 
high in 90 (82%) patients and medium in 20 (18%). In 4 (4%) patients, no side effects to adenosine 
(dyspnoea, chest, pain, dizziness, or headache) were registered, of whom 1 patient had a reversible 
perfusion defect (RPD). Left ventricular ejection fraction, mean (SD), by CMR was 66 (10). 
Irreversible perfusion defects were identified in 4 (4%) patients, all of whom had an RPD as well. 
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Of 83 (75%) patients, who were classified as having a normal CMR test result, 82 (99%) had 
completely normal stress perfusion. An RPD was demonstrated in 27 (25%) patients (small RPD: 
8/27 [30%]; moderate RPD: 13/27 [48%]; large RPD: 6/27 [22%]). The associations between the 
size of perfusion defects by CMR and the occurrence of significant CAD and revascularization are 
shown in Table 5. Of 8 patients diagnosed with an occluded coronary artery, 7 (88%) patients had an 
RPD by CMR.   
 
Head-to-head comparison, FFRCT versus CMR  
The number of patients classified as having obstructive CAD, n (%), differed between the non-
invasive modalities: FFRCT 79 (72) versus CMR 27 (25), p<0.001. Concordant FFRCT and CMR test 
results were found in 58 (53%) patients, of whom 27 (47%) patients had obstructive CAD by both 
tests and 31 (53%) patients normal test results by both FFRCT and CMR. In the former group, 
revascularization was performed in 18 (67%) patients, in the latter 1 (3%), p<0.001. Discordant test 
results were seen in 52 (47%) patients, all having a normal test result by CMR and signs of 
obstructive CAD by FFRCT, of whom 19 (37%) patients were revascularized. No patients were 
classified as abnormal by CMR and as normal by FFRCT.  
 
Prediction of revascularization, FFRCT versus CMR 
The per-patient diagnostic performance for identifying standard of care guided revascularization, 
(95% confidence interval) yielded a sensitivity of 97% (86-100) for FFRCT versus 47% (31- 64) by 
CMR, p < 0.001; corresponding specificity was 42% (30-54) versus 88% (78-94), p < 0.001; 
negative predictive value 97% (91-100) versus 76% (67-85), p<0.05; positive predictive value 47% 
(36-58) versus 67% (49-84), p<0.05; and accuracy 61% (51-70) versus 74% (64-82), respectively, 
p>0.05, Central Illustration. The sensitivity of FFRCT for predicting revascularization remained 
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constantly high in all tested strata, whereas the sensitivity of CMR was consistently low, Table 6. 
False-negative test results were more frequent by CMR, n=20, than classification of obstructive 
CAD by distal-tip FFRCT-values, n=1, p<0.001, both amongst patients, n (%), undergoing multi-
vessel revascularization: CMR 7 (50) versus FFRCT 0 (0), p<0.05, patients treated by single-vessel 
revascularization: CMR 13 (54) versus FFRCT 1 (4), p<0.001 and patients undergoing CABG: CMR 
8 (62) versus FFRCT 0 (0), p<0.01. Significantly more patients, n (%), with a false negative CMR 
test result compared to patients with a false negative FFRCT test result underwent revascularization 
for proximal LAD-stenosis: CMR 17 (61) versus FFRCT 0 (0), p<0.001, and had a stenosis 
severity >90% by ICA: CMR 14 (61) versus FFRCT 1 (4), p<0.01. The only patient, who was falsely 
classified as normal by FFRCT had a >90% stenosis of the RCA-1 and was treated directly with PCI.  
The diagnostic sensitivity of CMR was not different among patients with analysable 
coronary CTA datasets compared to patients in whom CTA datasets were rejected for FFRCT-
analysis: 18 of 38 (47%) versus 4 of 7 (57%), p>0.05. No difference in the diagnostic performance 
of CMR, regadenosone versus adenosine, was demonstrated (Data not shown).     
The specificity for predicting revascularization was significantly improved from 42% 
to 68%, p<0.001, by using lesion-specific FFRCT-values rather than distal-tip FFRCT-values for 
classification of obstructive CAD, which caused a non-significant decrease in test sensitivity of 
FFRCT from 97% to 84%, p>0.05, Central Illustration and Table 7.     
 
Discussion  
This prospective clinical study comparing FFRCT and CMR stress perfusion imaging in symptomatic 
stable patients with CAD as determined by coronary CTA did not show any difference in the 
diagnostic accuracy of FFRCT and CMR in predicting standard of care guided coronary 
revascularization. However, a significant difference in sensitivity in favour of FFRCT was 
	 	 	
	 12	
demonstrated, while the specificity of CMR was highest. The current study included patients in 
whom guidelines recommend adjunctive non-invasive functional testing. To avoid deferral from 
invasive investigation of obstructive coronary disease a high diagnostic sensitivity and negative 
predictive value of the second-line tests is essential. Accordingly, this first head-to-head comparison 
between second-line FFRCT and CMR testing strategies is relevant.  
In this study, patients undergoing revascularization were more often classified as having functional 
impairment by FFRCT as compared to CMR. These results are in line with two recent studies, in 
which FFRCT had a higher diagnostic sensitivity for prediction of revascularization compared to the 
severity of stenosis by coronary CTA (17) and compared to the occurrence of reversible perfusion 
defects by SPECT (9). Of note, clinical decision-making on revascularization in these studies was 
made independently of FFRCT-analyses, as test results were unknown to the caregivers.  
Several factors might influence the only modest diagnostic sensitivity of CMR stress 
perfusion imaging demonstrated in the present study. First, it should be recognized that studies 
included in recent meta-analyses (3,4) used CMR as a first line rule-out in patients with chest pain, 
while the current applied CMR as a second-line testing strategy solely in those patients who had 
documented CAD by coronary CTA. Second, the disease prevalence in the current study was lower 
than in previous studies. In the CE-MARC study 11 % of patients had a previous myocardial 
infarction or had undergone revascularization (18). In the MR-IMPACT-II study 39% sustained a 
previous infarction and 31% had been treated by coronary angioplasty in the past (19), while 
patients with known CAD were excluded in our study. Third, an anatomic/physiological mismatch is 
well-known (17, 20), implying that a number of lesions in prior studies presumably would have been 
re-classified, if physiologic measurements by FFR instead of morphologic degree stenosis by ICA 
had been used as the reference. Fourth, it might be argued that 3T scanners yielding higher spatial 
resolution and giving the potential for quantification of perfusion might have increased the 
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diagnostic sensitivity of CMR. However, 3T scanners have not been documented to yield superior 
results compared to 1.5 T systems and the latter scanner type is by far the most prevalent system 
used for CMR stress perfusion studies. Furthermore, quantitative measures of perfusion by CMR has 
not yet been fully established. Fifth, the threshold for a reversible perfusion defect by CMR stress 
perfusion imaging in this study was defined as >2 segments in accordance with international 
guidelines. Applying a lower threshold for test positivity would not have changed test sensitivity for 
CMR, as 82 out of 83 patients (99%) had completely normal CMR stress perfusion scans. Although 
a small myocardium-at-risk may be a reason for a false negative CMR scan (21), it is unlikely to 
explain the demonstrated low sensitivity of CMR, as 89% of treated lesions were located proximal 
in the coronary arteries. Moreover, the modest diagnostic sensitivity of CMR was demonstrated 
across subpopulations. Finally, the low diagnostic sensitivity of CMR in this study are unlikely to be 
caused by inappropriate CMR stress testing or data analysis, as 96% of patients had adverse effects 
during pharmacological stress testing and as 82% of CMR datasets had a good image quality.  
The low rate of patients classified with obstructive CAD by CMR may seem in 
contrast to the medium-to high burden of coronary atherosclerosis seen in patients in this study as 
illustrated by 40% of patients having an Agatston score above 400, 24% having a stenosis 
severity >90% and 35% undergoing revascularization of whom 37% were treated due to multi-
vessel disease and 34% were treated by CABG.  
The modest per-patient FFRCT specificity detected in this study may in part be 
explained by the use of distal-tip FFRCT-value rather than lesion-specific FFRCT-value (22). The 
increase in test specificity by applying lesion-specific FFRCT for categorizing patients was achieved 
with a non-significant decrease in test sensitivity, which is in accordance with a recent study (14). 
Still, the specificity of CMR remained significantly higher than that of FFRCT.  
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Similarities between the vessel specific approach elaborated by FFR and FFRCT as 
opposed to evaluation by myocardial perfusion by CMR would be in favour of FFRCT and an 
explanation for the difference in the diagnostic performance. However, FFRCT modelling and 
principles underlying computational fluid dynamics are fundamentally different from FFR. In 
addition, revascularization was guided not only by FFR-assessments but by angiography in 48% of 
patients in our study. 
How the differences of second-line FFRCT and CMR test performance influence 
outcomes in terms of prognosis/costs for societies is at the moment unsettled. However, testing 
strategies using either first-line CMR (23,24,25) or selective FFRCT (11) have both indicated a 
favorable prognosis considering death and myocardial infarction in stable patients with a normal test 
result and also a more favorable resource utilization compared to usage of first-line coronary 
angiography (26,27). The importance of choosing a first-line testing strategy with the ability to 
provide direct visualization of atherosclerotic coronary lesions has recently been demonstrated in the 
SCOT-HEART randomized trial (28), in a sub-study of the Prospective Multicentre Imaging Study 
for Evaluation of Chest Pain (PROMISE) trial (29) and by a meta-analysis (30), as the incidence of 
major adverse cardiovascular events was significantly lower following anatomic assessment by 
coronary CTA than following first-line functional testing strategies.  
 In this context, it is worth noticing that a number of obstructive lesions in the current 
study would have remained undiagnosed by CMR perfusion imaging, if invasive angiography had 
not been performed, which is of special importance because first-line CMR have indicated more 
favourable resource utilization than first-line coronary angiography. We did not include any follow-
up data on either symptomatic relief or incidence of coronary events in our study, so it remains 
unknown how the reported discrepancy in diagnostic performance of second-line FFRCT and CMR 
following a first-line coronary CTA impact resource utilization and patient outcomes. 
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Limitations  
The number of patients included in this prospective study is relatively small, which may give rise to 
spurious non-significant results. However, as our sample size was sufficient to detect significant 
differences between the main effect parameters, the diagnostic sensitivity and specificity of the two 
tests being compared, the risk of spurious non-significant results is not an issue for our primary 
outcomes. 
A number of patients were unable to complete all planned series of tests. Our rejection 
rate for FFRCT-analysis was 21%, and was higher than reported in previous studies, where CTA scan 
protocols were optimized for FFRCT-analysis (9, 10), but at the same level as in a study without pre-
scheduled FFRCT-analysis (17). As the proportion of patients undergoing revascularization and the 
diagnostic sensitivity of CMR were similar in drop-outs and in the study population, we do not 
believe this had any impact on the result of this study.  
The results of this study only apply to patients in whom coronary CTA testing is 
appropriate.  
 
Conclusion 
In patients with stable chest pain and documented CAD by coronary CTA adjunctive non-invasive 
functional testing by FFRCT and CMR yielded similar overall accuracy for prediction of coronary 
revascularization. However, a significant difference in diagnostic sensitivity in favour of FFRCT was 
demonstrated, while the specificity of CMR was highest. 
 
Clinical Perspective 
To the best of our knowledge, this prospective study is the first of its kind to compare the novel 
physiologic metric, FFRCT, with CMR stress perfusion imaging for prediction of standard of care 
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guided coronary revascularization in real-world practice. The current study in stable symptomatic 
patients with coronary lesions as determined by coronary CTA did not show any difference in the 
overall accuracy of FFRCT and CMR in predicting revascularization. However, FFRCT had a 
significantly higher diagnostic sensitivity than CMR in identifying patients undergoing 
revascularization, while the specificity was highest for CMR.  Randomized prospective trials are 
warranted to clarify, whether the reported discrepancy between the applied adjunctive functional 
testing strategies in selecting patients for invasive procedures will have significant impact on patient 
outcomes.   
 
Perspectives 
COMPETENCY IN MEDICAL KNOWLEDGE 
Functional testing is recommended prior to referral to invasive angiography in patients with stable 
chest pain and obstructive CAD as determined by coronary CTA. A direct comparison of the clinical 
utility of FFRCT and CMR as second-line sequential testing strategies has not previously been 
assessed.  In this study we found a similar diagnostic accuracy of the two non-invasive testing 
strategies for prediction of standard of care guided coronary revascularization. However, the 
diagnostic sensitivity was significantly higher for FFRCT compared to CMR, while the specificity 
was highest for CMR. 
 
TRANSLATIONAL OUTLOOK  
The reported diagnostic performance of second-line FFRCT and CMR following a first-line coronary 
CTA in patients with stable chest pain relates to prediction of standard of care guided 
revascularization. Large prospective studies are warranted to evaluate if the reported discrepancy 
impact resource utilization and patient outcomes. 
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Legends 
Figure 1. Flowchart. 
This study represents a sub-study of the Dan-NICAD-trial (Danish Study of Non-Invasive testing in 
Coronary Artery Disease (12). 
*CMR = Cardiac magnetic resonance; #CTA = Computed tomography angiography; §FFRCT = 
Fractional flow reserve derived from coronary CTA; †ICA = Invasive coronary angiography. 
 
Central Illustration. FFRCT compared with CMR stress perfusion imaging for prediction of 
standard of care guided coronary revascularization in patients with stable chest pain.  
FFRCT defined as the per-patient lowest FFRCT-value in coronary vessels >1.8 mm in diameter. The 
results of core laboratory FFRCT analysis and CMR test assessments had no impact on referral to 
invasive angiography and were blinded to decision makers. 
‡NPV = Negative predictive value; †PPV = Positive predictive value. Other abbreviations as in 
Figure 1. 
 
 
 
 
